Financial Performance - Net loss for Q1 fiscal 2025 was 14.5 million for the same period last year[5]. - Basic and diluted net loss per common share for Q1 fiscal 2025 was 0.28 for the same period last year[10]. - Total operating expenses for Q1 fiscal 2025 were 15.9 million for the same period last year[10]. Cash and Investments - Cash, cash equivalents, and investments in marketable securities totaled 127.1 million as of June 30, 2024[3]. - Working capital increased to 95.5 million a year ago[10]. - Total stockholders' equity rose to 103.6 million a year earlier[10]. Research and Development - Research and development expenses increased to 12.2 million for the same period last year, primarily due to higher clinical trial activities and personnel-related expenses[4]. - The Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism is on track, with U.S. enrollment expected to commence in early 2025 and topline results anticipated in the second half of 2025[2]. - Start-up activities for the Phase 3 registrational study for tumor hyperinsulinism are progressing, with patient enrollment expected to begin in the first half of 2025 and topline results expected in the second half of 2026[3]. General and Administrative Expenses - General and administrative expenses rose to 3.7 million year-over-year, driven by increased professional fees and employee-related expenses[5].
Rezolute(RZLT) - 2025 Q1 - Quarterly Results